Functional expression of human arylamine N-acetyltransferase NAT1*10 and NAT1*11 alleles: a mini review
- PMID: 30222709
- PMCID: PMC6208141
- DOI: 10.1097/FPC.0000000000000350
Functional expression of human arylamine N-acetyltransferase NAT1*10 and NAT1*11 alleles: a mini review
Abstract
The arylamine N-acetyltransferase (NAT) nomenclature committee assigns functional phenotypes for human arylamine N-acetyltransferase 1 (NAT1) alleles in those instances in which the committee determined a consensus has been achieved in the scientific literature. In the most recent nomenclature update, the committee announced that functional phenotypes for NAT1*10 and NAT1*11 alleles were not provided owing to a lack of consensus. Phenotypic inconsistencies observed among various studies for NAT1*10 and NAT1*11 may be owing to variable allelic expression among different tissues, the limitations of the genotyping assays (which mostly relied on techniques not involving direct DNA sequencing), the differences in recombinant protein expression systems used (bacteria, yeast, and mammalian cell lines) and/or the known inherent instability of human NAT1 protein, which requires very careful handling of native and recombinant cell lysates. Three recent studies provide consistent evidence of the mechanistic basis underlying the functional phenotype of NAT1*10 and NAT1*11 as 'increased-activity' alleles. Some NAT1 variants (e.g. NAT1*14, NAT1*17, and NAT1*22) may be designated as 'decreased-activity' alleles and other NAT1 variants (e.g. NAT1*15 and NAT1*19) may be designated as 'no-activity' alleles compared with the NAT1*4 reference allele. We propose that phenotypic designations as 'rapid' and 'slow' acetylator should be discontinued for NAT1 alleles, although these designations remain very appropriate for NAT2 alleles.
Conflict of interest statement
Conflicts of interest
There are no conflicts of interest.
Figures

Similar articles
-
Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases.Carcinogenesis. 1993 Aug;14(8):1633-8. doi: 10.1093/carcin/14.8.1633. Carcinogenesis. 1993. PMID: 8353847
-
Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes.Mol Pharmacol. 1991 Feb;39(2):184-91. Mol Pharmacol. 1991. PMID: 1996083
-
Human acetyltransferase polymorphisms.Mutat Res. 1997 May 12;376(1-2):61-70. doi: 10.1016/s0027-5107(97)00026-2. Mutat Res. 1997. PMID: 9202739
-
Regulation of the activity of the human drug metabolizing enzyme arylamine N-acetyltransferase 1: role of genetic and non genetic factors.Curr Pharm Des. 2004;10(20):2519-24. doi: 10.2174/1381612043383845. Curr Pharm Des. 2004. PMID: 15320760 Review.
-
Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms.Cancer Epidemiol Biomarkers Prev. 2000 Jan;9(1):29-42. Cancer Epidemiol Biomarkers Prev. 2000. PMID: 10667461 Review.
Cited by
-
Red meat consumption, cooking mutagens, NAT1/2 genotypes and pancreatic cancer risk in two ethnically diverse prospective cohorts.Int J Cancer. 2021 Apr 12:10.1002/ijc.33598. doi: 10.1002/ijc.33598. Online ahead of print. Int J Cancer. 2021. PMID: 33844845 Free PMC article.
-
Humans and Chimpanzees Display Opposite Patterns of Diversity in Arylamine N-Acetyltransferase Genes.G3 (Bethesda). 2019 Jul 9;9(7):2199-2224. doi: 10.1534/g3.119.400223. G3 (Bethesda). 2019. PMID: 31068377 Free PMC article.
-
Multigene Panel Germline Testing of 1333 Czech Patients with Ovarian Cancer.Cancers (Basel). 2020 Apr 13;12(4):956. doi: 10.3390/cancers12040956. Cancers (Basel). 2020. PMID: 32295079 Free PMC article.
-
Hypermethylation of N-Acetyltransferase 1 Is a Prognostic Biomarker in Colon Adenocarcinoma.Front Genet. 2019 Nov 6;10:1097. doi: 10.3389/fgene.2019.01097. eCollection 2019. Front Genet. 2019. PMID: 31781164 Free PMC article.
-
560G>A (rs4986782) (R187Q) Single Nucleotide Polymorphism in Arylamine N-Acetyltransferase 1 Increases Affinity for the Aromatic Amine Carcinogens 4-Aminobiphenyl and N-Hydroxy-4-Aminobiphenyl: Implications for Cancer Risk Assessment.Front Pharmacol. 2022 Feb 22;13:820082. doi: 10.3389/fphar.2022.820082. eCollection 2022. Front Pharmacol. 2022. PMID: 35273499 Free PMC article.
References
-
- Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DA, Grant DM, et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995;5:1–17. - PubMed
-
- Hein DW, Grant DM, Sim E. Update on consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenetics 2000;10:291–2. - PubMed
-
- Boukouvala S, Westwood IM, Butcher NJ, Fakis G. Current trends in N-acetyltransferase research arising from the 2007 International NAT Workshop. Pharmacogenomics 2008;9:765–71. - PubMed
-
- Vatsis KP, Weber WW. Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus. Arch Biochem Biophys 1993;301:71–6. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources